Interventional Cardiologists to Discuss Current Challenges Facing Cath Labs and Offer Potential Solutions During Evening Event at SCAI 2015
Waltham, MA –May 5, 2015 – Corindus Vascular Robotics, Inc. [OTCQB: CVRS], a leading developer of precision vascular robotics, will sponsor a dinner event during the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego, California. The dinner event, “21st Century Solutions to the Current Cath Lab Challenges: UC San Diego Approach,” will take place on Thursday, May 7, from 7 – 9 p.m. at the UC San Diego (UCSD) Medical Center, and will feature Dr. Ehtisham Mahmud, Chief of Cardiovascular Medicine, Director of Sulpizio Cardiovascular Center at UCSD, who will discuss cath lab economics of simple and complex PCI.
Attendees of the dinner event will also hear from Anthony DeMaria, MD, MACC, Professor of Medicine, Founding Director, Sulpizio Cardiovascular Center, University of California, San Diego about his view on the “Future of Cardiology;” Manos Brilikas, MD, Director, VAMC Catheterization Lab, UT Southwestern, about the hazards of working in the cath lab; and Giora Weisz, MD, FACC, FSCAI, Chairman, Department of Cardiology, Shaare Zedek Medical Center about the benefits of robotic-assisted PCI.
Dinner guests will also have the opportunity to tour the UC San Diego Medical Center’s catheterization lab and see how robotics can be applied to complex PCI within the lab’s daily workflow. In addition to allowing cardiologists to advance stents and guidewires millimeter-by-millimeter using digital controls, the CorPath System enables physicians to perform procedures while seated in a lead-lined interventional cockpit protected from radiation exposure.
In addition to sponsoring the dinner event, Corindus will showcase its technology in booth #313 at SCAI 2015. Attendees are invited to perform a CorPath robotic-assisted PCI using a virtual reality simulator in the booth.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: